ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.

about

ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.

Item

http://www.wikidata.org/entity/Q47575958

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

ALK expression plays different ...... ients in a Chinese population.

@en

ALK expression plays different ...... ients in a Chinese population.

@nl

type

Item

label

ALK expression plays different ...... ients in a Chinese population.

@en

ALK expression plays different ...... ients in a Chinese population.

@nl

prefLabel

ALK expression plays different ...... ients in a Chinese population.

@en

ALK expression plays different ...... ients in a Chinese population.

@nl

P1476

ALK expression plays different ...... ients in a Chinese population.

@en

P2093

Feili Chen

http://www.w3.org/2001/XMLSchema#string

Fen Zhang

http://www.w3.org/2001/XMLSchema#string

Hanguo Guo

http://www.w3.org/2001/XMLSchema#string

Jialong Zeng

http://www.w3.org/2001/XMLSchema#string

Ling Huang

http://www.w3.org/2001/XMLSchema#string

Sichu Liu

http://www.w3.org/2001/XMLSchema#string

Xiaojuan Wei

http://www.w3.org/2001/XMLSchema#string

Xinmiao Jiang

http://www.w3.org/2001/XMLSchema#string

Yanhui Liu

http://www.w3.org/2001/XMLSchema#string

Zhanli Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center

The biology and management of systemic anaplastic large cell lymphoma

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Crizotinib in anaplastic large-cell lymphoma.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

P304

149-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3166-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Wenyu Li

P577

2017-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29150811

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib